Диссертация (1174200), страница 53
Текст из файла (страница 53)
Schulman S. Post‐thrombotic syndrome, recurrence, and death 10 years after thefirst episode of venous thromboembolism treated with warfarin for 6 weeks or 6months / S. Schulman [et al.] // Journal of Thrombosis and Haemostasis. – 2006. –Т. 4. – № 4. – P. 734-742.302. Schulman S. Hemorrhagic complications of anticoagulant and thrombolytictreatment: American College of Chest Physicians evidence-based clinical practiceguidelines / S. Schulman [et al.] // Chest. – 2008. – Т. 133.
– № 6. – P. 257S-298S.303. Schulman S. Treatment of acute venous thromboembolism with dabigatran orwarfarin and pooled analysis / S. Schulman [et al.] // Circulation. – 2014. – Т. 129.– № 7. – P. 764-772.304. Schulman S. Venous thromboembolism: past, present and future / S. Schulman, W.Ageno, S.V. Konstantinides // Thrombosis and haemostasis. – 2017. – Т. 117. –№ 7. – P. 1219-1229.305. Schultz D.J. Incidence of asymptomatic pulmonary embolism in moderately toseverely injured trauma patients / D.J. Schultz [et al.] // Journal of Trauma andAcute Care Surgery.
– 2004. – Т. 56. – № 4. – P. 727-733.306. Schwarz T. Eligibility for home treatment of deep vein thrombosis: prospectivestudy / T. Schwarz [et al.] // Bmj. – 2001. – Т. 322. – № 7296. – P. 1212-1213.307. Secemsky E.A. Inferior Vena Cava Filters and Mortality: Is It the UnderlyingProcess, the Patient, or the Device? / E.A. Secemsky, B.J. Carroll, R.W. Yeh //JAMA network open. – 2018. – Т.
1. – № 3. – P. e180453–e180453.308. Serhal M. Pulmonary embolism response teams / M. Serhal [et al.] // Journal ofthrombosis and thrombolysis. – 2017. – Т. 44. – № 1. – P. 19-29.309. Smith S.B. Analysis of national trends in admissions for pulmonary embolism /S.B. Smith [et al.] // Chest. – 2016.
– Т. 150. – № 1. – P. 35-45.310. Snow V. Management of venous thromboembolism: a clinical practice guidelinefrom the American College of Physicians and the American Academy of FamilyPhysicians / V. Snow [et al.] // Annals of Internal Medicine. – 2007. – Т. 146. –№ 3. – P. 204-210.318311. Southworth M.R. Dabigatran and postmarketing reports of bleeding / M.R.Southworth, M.E. Reichman, E.F.
Unger // New England Journal of Medicine. –2013. – Т. 368. – № 14. – P. 1272-1274.312. Spahn D.R. Management of bleeding and coagulopathy following major trauma:an updated European guideline / D.R. Spahn [et al.] // Critical care. – 2013. –Т. 17. – № 2. – P. 1-45.313. Spencer F.A. The Worcester Venous Thromboembolism study: a population‐basedstudy of the clinical epidemiology of venous thromboembolism / F.A. Spencer [etal.] // Journal of general internal medicine. – 2006. – Т. 21. – № 7.
– P. 722-727.314. Spencer F.A. A population-based study of inferior vena cava filters in patients withacute venous thromboembolism / F.A. Spencer [et al.] // Archives of internalmedicine. – 2010. – Т. 170. – № 16. – P. 1456-1462.315. Spenser F.C. Plication of inferior vena cava for pulmonary embolism / F.C.Spenser, J.K. Quattlebaum, E.H. Charp // Ann Surg. – 1962. – Т. 155. – № 6. –P. 827-837.316. Spyropoulos A.C.
Management of acute proximal deep vein thrombosis:pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatienttreatment with unfractionated heparin / A.C. Spyropoulos [et al.] // Chest. – 2002.– Т. 122. – № 1. – P. 108-114.317. Stavropoulos S.W. Analysis of the final DENALI trial data: a prospective,multicenter study of the Denali inferior vena cava filter / S.W. Stavropoulos [et al.]// Journal of Vascular and Interventional Radiology. – 2016. – Т.
27. – № 10. –P. 1531-1538.318. Stein P.D. Outcome and complications of retrievable inferior vena cava filters /P.D. Stein [et al.] // The American journal of cardiology. – 2004. – Т. 94. – № 8. –P. 1090-1093.319. Stein P.D. Impact of vena cava filters on in-hospital case fatality rate frompulmonary embolism / P.D.
Stein [et al.] // The American journal of medicine. –2012. – Т. 125. – № 5. – P. 478–484.319320. Stein P.D. Underuse of vena cava filters in unstable patients with acute pulmonaryembolism / P.D. Stein, J.E. Dalen, F. Matta // The American journal of medicine. –2014. – Т. 127.
– № 1. – P. 6.321. Stein P.D. Twenty-one-year trends in the use of inferior vena cava filters / P.D.Stein, F. Kayali, R.E. Olson // Archives of internal medicine. – 2004. – Т. 164. –№ 14. – P. 1541-1545.322. Stein P.D. Vena cava filters in unstable elderly patients with acute pulmonaryembolism / P.D. Stein, F. Matta // The American journal of medicine. – 2014. –Т. 127. – № 3. – P. 222-225.323. Stein P.D. Increasing use of vena cava filters for prevention of pulmonaryembolism / P.D. Stein, F. Matta, R.D. Hull // The American journal of medicine.
–2011. – Т. 124. – № 7. – P. 655-661.324. Streiff M.B. Vena caval filters: a comprehensive review / M.B. Streiff // Blood.2000. – Т. 95. – № 12. – P. 3669-3677.325. Surie S. Active search for chronic thromboembolic pulmonary hypertension doesnot appear indicated after acute pulmonary embolism / S. Surie [et al.] //Thrombosis research. – 2010. – Т. 125. – № 5. – P. 202-205.326. Sutphin P.D. Improving inferior vena cava filter retrieval rates with the define,measure, analyze, improve, control methodology / P.D. Sutphin [et al.] // Journalof Vascular and Interventional Radiology. – 2015. – Т. 26.
– № 4. – P. 491-498.327. Taccone F.S. A new device for the prevention of pulmonary embolism in criticallyill patients: Results of the European Angel Catheter Registry / F.S. Taccone [et al.]// Journal of Trauma and Acute Care Surgery. – 2015. – Т. 79. – № 3. – P. 456462.328. Tadlock M.D. The origin of fatal pulmonary emboli: a postmortem analysis of 500deaths from pulmonary embolism in trauma, surgical, and medical patients / M.D.Tadlock [et al.] // The American Journal of Surgery. – 2015. – Т.
209. – № 6. –P. 959-968.329. Tagalakis V. Incidence of and mortality from venous thromboembolism in a realworld population: the Q-VTE Study Cohort / V. Tagalakis [et al.] // The American320journal of medicine. – 2013. – Т. 126. – № 9. – P. 832. – Mode of access:https://doi.org/10.1016/j.amjmed.2013.02.024.330. Tagalakis V. Treatment patterns of venous thromboembolism in a real-worldpopulation: the Q-VTE study cohort / V. Tagalakis [et al.] // Thrombosis research.– 2014. – Т.
134. – № 4. – P. 795-802.331. Tao M.J. Temporary inferior vena cava filter indications, retrieval rates, andfollow-up management at a multicenter tertiary care institution / M.J. Tao [et al.] //Journal of vascular surgery. – 2016. – Т. 64. – № 2. – P. 430-437.332. Tapson V.F. Acute pulmonary embolism / V.F. Tapson // New England Journal ofMedicine. – 2008. – Т. 358. – № 10. – P. 1037-1052.333. Tapson V.F. Evaluation of a device combining an inferior vena cava filter and acentral venous catheter for preventing pulmonary embolism among critically illtrauma patients / V.F. Tapson [et al.] // Journal of Vascular and InterventionalRadiology.
– 2017. – Т. 28. – № 9. – P. 1248-1254.334. Tapson V.F. Systemic thrombolysis for pulmonary embolism: who and how / V.F.Tapson, O. Friedman // Techniques in vascular and interventional radiology. –2017. – Т. 20. – № 3. – P. 162-174.335. Tiede H. Global burden of chronic thromboembolic pulmonary hypertension(CTEPH): an epidemiological analysis / H. Tiede [et al.] // Eur Respir J. – 2014. –Т.
44. – № Suppl 58. – P. P2326.336. Timp J.F. Epidemiology of cancer-associated venous thrombosis / J.F. Timp [etal.] // Blood. – 2013. – Т. 122. – № 10. – P. 1712-1723.337. Tomaselli G.F. ACC expert consensus decision pathway on management ofbleeding in patients on oral anticoagulants: a report of the American College ofCardiology Task Force on Expert Consensus Decision Pathways / G.F.
Tomaselli[et al.] // Journal of the American College of Cardiology. – 2017. – Т. 70. – № 24.– P. 3042-3067.338. Tornkvist M. Current evidence of oral anticoagulant reversal: A systematic review/ M. Tornkvist, J.G. Smith, A. Labaf // Thrombosis research. – 2018. – Т. 162. –P. 22-31.321339. Tosetto A. Predicting disease recurrence in patients with previous unprovokedvenous thromboembolism: a proposed prediction score (DASH) / A. Tosetto [etal.] // Journal of thrombosis and haemostasis.
– 2012. – Т. 10. – № 6. – P. 10191025.340. Triplett D.A. The effect of heparin on the activated partial thromboplastin time. /D.A. Triplett, C.S. Harms, J.A. Koepke // American journal of clinical pathology.– 1978. – Т. 70. – № 3 Suppl. – P. 556-559.341. Tritschler T.
Predicting recurrence after unprovoked venous thromboembolism:prospective validation of the updated Vienna Prediction Model / T. Tritschler [etal.] // Blood. – 2015. – Т. 126. – № 16. – P. 1949-1951.342. Turner T.E. Association of inferior vena cava filter placement for venousthromboembolic disease and a contraindication to anticoagulation with 30-daymortality / T.E. Turner [et al.] // JAMA network open. – 2018. – Т. 1. – № 3. –P. 1-9.343. Uppal B.
The bedside insertion of inferior vena cava filters using ultrasoundguidance / B. Uppal, W.R. Flinn, M.E. Benjamin // Perspectives in vascularsurgery and endovascular therapy. – 2007. – Т. 19. – № 1. – P. 78-84.344. Usoh F. Long-term follow-up for superior vena cava filter placement / F. Usoh [etal.] // Annals of vascular surgery. – 2009.
– Т. 23. – № 3. – P. 350-354.345. Van der Hulle T. Effectiveness and safety of novel oral anticoagulants as comparedwith vitamin K antagonists in the treatment of acute symptomatic venousthromboembolism: a systematic review and meta‐analysis / T. Van der Hulle [etal.] // Journal of Thrombosis and Haemostasis. – 2014. – Т. 12. – № 3. – P. 320328.346. Van Haren R.M.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
